Lexeo Therapeutics Ownership | Who Owns Lexeo Therapeutics?

Lexeo Therapeutics Ownership Summary

Lexeo Therapeutics is owned by 3.61% institutional investors, 0.56% insiders, and 95.84% retail investors. Vanguard group is the largest institutional shareholder, holding 6.39% of LXEO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.05% of its assets in Lexeo Therapeutics shares.

LXEO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Lexeo Therapeutics	3.61%	0.56%	95.84%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	3.89M	6.39%	$38.67M
Adar1 capital management	1.53M	3.52%	$10.17M
D1 capital partners	978.65K	2.25%	$6.50M
Paradigm biocapital advisors lp	6.18M	1.15%	$35.50M
Blackrock funding, inc. /de	5.11M	0.95%	$29.34M
Affinity asset advisors	5.05M	0.94%	$28.99M
Ra capital management	5.00M	0.93%	$28.70M
Janus henderson group	4.98M	0.93%	$28.51M
Vestal point capital, lp	4.47M	0.83%	$25.69M
Frazier life sciences management	4.42M	0.82%	$25.40M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Caxton	13.94K	1.99%	$80.03K
Affinity asset advisors	5.05M	1.50%	$28.99M
Adar1 capital management	1.53M	0.96%	$10.17M
Paradigm biocapital advisors lp	6.18M	0.73%	$35.50M
Vestal point capital, lp	4.47M	0.72%	$25.69M
Octagon capital advisors lp	1.10M	0.70%	$6.31M
Frazier life sciences management	4.42M	0.65%	$25.40M
Dafna capital management	377.06K	0.49%	$2.16M
Orbimed advisors	3.60M	0.41%	$20.68M
683 capital management	1.20M	0.36%	$6.89M

Top Buyers

Holder	Shares	% Assets	Change
Affinity asset advisors	5.05M	1.50%	1.85M
Vanguard group	3.89M	0.00%	1.67M
Orbimed advisors	3.60M	0.41%	1.48M
Paradigm biocapital advisors lp	6.18M	0.73%	1.42M
Adar1 capital management	1.53M	0.96%	1.39M

Top Sellers

Holder	Shares	% Assets	Change
Avoro capital advisors	1.88M	0.11%	-1.43M
Eventide asset management	-	-	-1.23M
Omega fund management	-	-	-1.18M
Novo	-	-	-1.12M
Ally bridge group (ny)	-	-	-867.30K

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	384.73K	0.00%	384.73K	$2.21M
Abrdn	245.90K	0.00%	245.90K	$1.41M
Drw securities	47.99K	0.00%	47.99K	$275.45K
Bleakley financial group	47.96K	0.00%	47.96K	$275.31K
Vanguard global advisers	42.58K	0.00%	42.58K	$244.38K

Sold Out

Holder	Change
Rothschild investment	-1.00
Clearstead advisors	-4.00
Rialto wealth management	-53.00
Farther finance advisors	-57.00
Coldstream capital management	-93.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	77	-47.26%	19,349,588	-74.69%	3	0.02%	46	-56.19%	21	-22.22%
Dec 31, 2025	111	-	46,081,879	-6.64%	75	1.15%	83	7.79%	17	13.33%
Sep 30, 2025	108	20.00%	49,357,573	16.76%	113	0.70%	74	34.55%	15	-
Jun 30, 2025	89	2.30%	42,266,176	54.77%	127	1.88%	54	35.00%	15	-34.78%
Mar 31, 2025	91	4.60%	28,007,979	-3.59%	84	1.10%	42	-26.32%	23	109.09%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	2.26M	3.05%	-
State Street® SPDR® S&P® Biotech ETF	2.03M	2.74%	-15.05K
iShares Russell 2000 ETF	1.57M	2.12%	13.21K
Vanguard Institutional Extnd Mkt Idx Tr	676.06K	0.91%	3.89K
Janus Henderson Gbl Life Sciences Divers	642.30K	0.87%	642.30K
Janus Henderson Global Life Sciences	633.49K	0.86%	934.00
Janus Henderson Global Life Sciences D	633.49K	0.86%	2.70K
Fidelity Small Cap Index	616.93K	0.83%	6.07K
Janus Henderson Glb Life Scn I2 USD	580.79K	0.78%	-9.05K
Janus Global Life Science AUSD	580.79K	0.78%	21.17K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 18, 2026	Otero Jose Manuel	Chief Operating Officer	Sell	$6.61K
May 18, 2026	Townsend Richard Nolan	Chief Executive Officer	Sell	$16.93K
Apr 06, 2026	Townsend Richard Nolan	Chief Executive Officer	Sell	$313.14K
Feb 18, 2026	Otero Jose Manuel	Chief Operating Officer	Sell	$19.29K
Feb 18, 2026	Townsend Richard Nolan	Chief Executive Officer	Sell	$64.92K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	3
2026 Q1	-	2
2025 Q4	-	14
2025 Q3	-	5
2025 Q2	-	4

LXEO Ownership FAQ

Who Owns Lexeo Therapeutics?

Lexeo Therapeutics shareholders are primarily institutional investors at 3.61%, followed by 0.56% insiders and 95.83% retail investors. The average institutional ownership in Lexeo Therapeutics's industry, Biotech Stocks , is 35.75%, which Lexeo Therapeutics falls below.

Who owns the most shares of Lexeo Therapeutics?

Lexeo Therapeutics’s largest shareholders are Vanguard group (3.89M shares, 6.39%), Adar1 capital management (1.53M shares, 3.52%), and D1 capital partners (978.65K shares, 2.25%). Together, they hold 12.15% of Lexeo Therapeutics’s total shares outstanding.

Does Blackrock own Lexeo Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Lexeo Therapeutics.

Who is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested?

Caxton is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.99% of its assets in 13.94K Lexeo Therapeutics shares, valued at 80.03K$.

Who is the top mutual fund holder of Lexeo Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Lexeo Therapeutics shares, with 3.05% of its total shares outstanding invested in 2.26M Lexeo Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools